Moderna Leads S&P 500 With Massive 2026 Rally

October 11, 2026 - 09:54

Moderna has become the standout performer in the S&P 500 this year, with shares climbing roughly 663 percent since January. The surge has surprised many analysts who expected artificial intelligence companies to dominate the index once again. Instead, the vaccine maker has outpaced every other stock in the benchmark, including the major chip and software names that captured attention throughout 2025.

The rally gained fresh momentum this week as investors await a critical data readout. Moderna is scheduled to release full results from its late stage cancer vaccine trial on October 24. The study combines the company's mRNA platform with an established immunotherapy treatment, and early signs have raised hopes that the approach could change how certain tumors are treated.

A positive result would open a market far larger than the company's original COVID business, which has faded as demand settled into a seasonal pattern. Analysts note that the stock remains volatile, and any disappointment in the October data could erase a significant portion of this year's gains. Even so, the run has already made Moderna the most talked about name on trading desks, and the upcoming announcement is expected to draw intense scrutiny from both Wall Street and the medical community.